“While we continue to navigate through an inflationary cost environment and manage supply chain challenges, we remain confident in the initiatives we are taking to further improve manufacturing efficiencies and operating performance,” said Keith A. Harvey, President and Chief Executive Officer. “As we look to the remainder of the year, we reiterate our outlook and continue to anticipate a year-over-year increase in value added revenue of 20% to 25% and a consolidated adjusted EBITDA margin of 17% to 20% for the full year 2022. In line with the outlook provided for our full year major maintenance spending, we expect second quarter major maintenance expense to be approximately $8 million to $10 million higher than the first quarter due to the timing of projects planned at several facilities,” concluded Mr. Harvey.
AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis
AbbVie Inc (NYSE:ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK…